Cargando…

PB2360: QUALITY OF LIFE AND TREATMENT SATISFACTION AMONG PATIENTS UNDER LONG-TERM ANTICOAGULANT THERAPY WITH VITAMIN K ANTAGONISTS

Detalles Bibliográficos
Autores principales:	Varaklioti, A., Nika, S., Papachronis, A., Chanos, A., Gkotsi, S., Pyrpyri, T., Sergentanis, T., Gavalaki, M., Katsarou, O.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429850/ http://dx.doi.org/10.1097/01.HS9.0000852264.69934.92

Ejemplares similares

PB2360: HIV-ASSOCIATED BURKITT LYMPHOMA IN THE COMBINATION ANTIRETROVIRAL THERAPY ERA: REAL-WORLD OUTCOMES AND PROGNOSTICATION
por: Wang, Chaoyu, et al.
Publicado: (2023)

PB2305: EFGARTIGIMOD: CLINICAL DEVELOPMENT OF A NOVEL FCRN ANTAGONIST IN THE TREATMENT OF AUTOIMMUNE DISEASES
por: Knoebl, P., et al.
Publicado: (2022)

PB2191: A RETROSPECTIVE MULTI-CENTER STUDY ON DIRECT ORAL ANTICOAGULANT USE IN BCR::ABL1 NEGATIVE MYELOPROLIFERATIVE NEOPLASMS
por: Baysal, Mehmet, et al.
Publicado: (2023)

PB2548: COMPARISON BETWEEN WEEKLY INTRAVENOUS VERSUS DAILY ORAL VITAMIN B12 SUPPLEMENTATION IN ANEMIA WITH VITAMIN B12 DEFICIENCY
por: Modak, Ketan, et al.
Publicado: (2023)

PB2043: CLINICAL EFFECTIVENESS, TREATMENT USE, SATISFACTION AND IMPACT ON QUALITY-OF-LIFE OF PEGCETACOPLAN TREATMENT FOR PATIENTS WITH PAROXYSMAL NOCTURNAL HAEMOGLOBINURIA (PNH).
por: Wilson, Koo, et al.
Publicado: (2023)

PB1938: 4WHIM: EVALUATING MAVORIXAFOR, AN ORAL CXCR4 ANTAGONIST, IN PATIENTS WITH WHIM SYNDROME VIA A GLOBAL PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED TRIAL WITH OPEN-LABEL EXTENSION
por: Dale, D. C., et al.
Publicado: (2022)

PB2351: ANXIETY AT THE HEMATOLOGIST
por: Trojan, S., et al.
Publicado: (2022)

PB2346: COMPARISON OF PRESCRIBING ERRORS WITH DIRECT ORAL ANTICOAGULANTS BETWEEN PAPER BASED AND ELECTRONIC BASED PRESCRIBING METHODS AT A REGIONAL BASE HOSPITAL IN NSW, AUSTRALIA
por: Glendinning, D., et al.
Publicado: (2022)

PB2363: REPORTING LANGUAGE IN HAEMATOLOGICAL MALIGNANCIES
por: Watt, S., et al.
Publicado: (2022)

PB2327: BONE MARROW STUDY IN THROMBOPENIA
por: López De Ugarriza, P., et al.
Publicado: (2022)

PB1757: VARIANT PHILADELPHIA CHROMOSOME IN ALL
por: Bouayed Abdelmoula, N., et al.
Publicado: (2022)

PB2622: A PROSPECTIVE, OPEN-LABEL ONGOING STUDY OF SAFETY AND TREATMENT SATISFACTION IN ADULT IMMUNE THROMBOCYTOPENIA (ITP) SUBJECTS AFTER SWITCHING TO AVATROMBOPAG FROM ELTROMBOPAG OR ROMIPLOSTIM
por: Kolodny, Scott, et al.
Publicado: (2023)

PB2056: PREVALENCE OF CLINICALLY SIGNIFICANT EXTRAVASCULAR HEMOLYSIS IN STABLE C5 INHIBITOR-TREATED PATIENTS WITH PNH AND ITS ASSOCIATION WITH DISEASE CONTROL, QUALITY OF LIFE AND TREATMENT SATISFACTION
por: Kulasekararaj, Austin, et al.
Publicado: (2023)

PB1861: ACALABRUTINIB IN THE TREATMENT OF RICHTER SYNDROME
por: Byalik, T., et al.
Publicado: (2022)

PB1827: ACUTE PROMYELOCYTIC LEUKEMIA IN THE ELDERLY
por: Marques, I., et al.
Publicado: (2022)

PB1952: CLL IN AYA
por: Mohamed, Shehab, et al.
Publicado: (2023)

PB1754: TELOMERE LENGTH IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA
por: Vakonaki, E., et al.
Publicado: (2022)

PB2201: THYMUS DEVELOPMENT IN CONGENITAL HEART DISEASES
por: Bódi, I., et al.
Publicado: (2022)

PB1969: FUNCTIONAL CHARACTERIZATION OF SUSCEPTIBILITY LOCI TO MULTIPLE MYELOMA
por: Shokouhi, M., et al.
Publicado: (2022)

PB1868: EXPERIENCE IN THE TREATMENT OF HAIRY CELL LEUKEMIA IN KAZAKHSTAN.
por: Kemelbekov, N., et al.
Publicado: (2022)

PB2166: TET ENZYMES PROTECT AGAINST FATAL LYMPHOPROLIFERATION
por: Spoeck, S., et al.
Publicado: (2022)

PB1867: PURINE ANALOGS ON HAIRY CELL LEUKAEMIA TREATMENT
por: Gomes, G., et al.
Publicado: (2022)

PB1931: HEMATOLOGICAL COMPLICATIONS OF COVID IMMUNIZATION-CASE SERIES
por: Aribandi, A., et al.
Publicado: (2022)

PB1918: MOLECULAR CHARACTERIZATION AND CLINICAL RELEVANCE OF ERYTHROPOIESIS IN MIELODYSPLASTIC SYNDROMES.
por: Villalba, A., et al.
Publicado: (2022)

PB1916: SOMATIC MUTATIONS ASSOCIATED WITH MYELODYSPLASTIC SYNDROME IN RUSSIAN PATIENTS
por: Kohno, A., et al.
Publicado: (2022)

PB2350: SAFETY AND EFFICACY OF HYPODERMOCLYSIS IN PATIENTS WITH HEMATOLOGICAL CANCERS
por: Kodru, A., et al.
Publicado: (2022)

PB2049: MEXICAN REGISTRY OF MYELOPROLIFERATIVE NEOPLASMS. INITIAL REPORT
por: De La Peña Celaya, J. A., et al.
Publicado: (2022)

PB2204: THE ROLE OF HES6 IN NORMAL HUMAN HEMATOPOIESIS
por: De Vos, T., et al.
Publicado: (2022)

PB2344: RESILIENCE IN PATIENTS WITH LYMPHOID MALIGNANCIES: THE REPLY STUDY.
por: Dos Santos, G., et al.
Publicado: (2022)

PB1963: A RARE CASE OF MULTIPLE SOLITARY PLASMOCYTOMA
por: Mlayah, Z., et al.
Publicado: (2022)

PB1900: COVID-19 IMPACT ON CHRONIC MYELOID LEUKEMIA PATIENTS
por: Galdean, S.-M., et al.
Publicado: (2022)

PB1932: GENERIC ELTHROMBOPAG WITH STANDARD IMMUNOSUPPRESSIVE THERAPY IN SEVERE APLASTIC ANEMIA
por: Ranjit Kumar, C., et al.
Publicado: (2022)

PB2287: END OF LIFE TRANSFUSIONS IN PATIENTS WITH AN ONCOLOGICAL DIAGNOSIS
por: Duque, L., et al.
Publicado: (2022)

PB1859: DEFINING T-CELL POPULATIONS IN CHRONIC LYMPHOCYTIC LEUKAEMIA
por: Mora, A., et al.
Publicado: (2022)

PB2053: PRIMARY ARTERIAL HYPERTENSION IN MYELOPROLIFERATIVE NEOPLASMS: A SYSTEMATIC REVIEW
por: Gaman, M.-A., et al.
Publicado: (2022)

PB2050: EVALUATION OF NON-CLONAL ERYTHROCYTOSIS: SINGLE CENTRE EXPERIENCE
por: Šumah, A., et al.
Publicado: (2022)

PB2120: HIV AND MALIGNANT HEMOPATHIES
por: Khibri, H., et al.
Publicado: (2022)

PB2564: COVID-19 AND FERRITIN
por: Kuiavovych, Bohdana, et al.
Publicado: (2023)

PB2274: A PROGNOSTIC MODEL TO PREDICT MORTALITY IN ICU DEPARTMENT OF HEMATOLOGY CLINIC
por: Luchinin, A., et al.
Publicado: (2022)

PB2075: CRYSTAL STORING HISTIOCYTOSIS PRESENTING AS HEAD AND NECK TUMORS
por: De La Flor Weiss, E. P., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_0a7oo0p3tovaf5b4sic503i5s9